A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Exclusion Criteria

• •Has segmental vitiligo
• •Has ≥50% leukotrichia on face or body
• •Has any other dermatological diseases that would interfere with vitiligo assessments
• •Has history of or current inflammatory condition other than vitiligo that, in the opinion of the investigator, could interfere with the evaluation of vitiligo
• •Has a known systemic hypersensitivity to interleukin 2 (IL-2), or modified IL-2 including MK-6194, or its inactive ingredients
• •Has an active or clinically significant infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks prior to Randomization, or oral/intramuscular anti-infective therapy within 2 weeks prior to Randomization
• •Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening
• •Has a severe chronic pulmonary disease requiring oxygen therapy
• •Has a transplanted organ, which requires continued immunosuppression
• •Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix
• •Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB
• •Has confirmed or suspected COVID-19 infection
• •Has history of drug or alcohol abuse within 6 months prior to Screening
• •Has had major surgery within 3 months prior to Screening OR has a major surgery planned during the study
• •Has had an inadequate response (as evaluated by a dermatologist or local physician specialist equivalent) to previous treatment with a Janus kinase inhibitor (JAKi) after an appropriate treatment duration (eg, ≥12 weeks)
• •Has received prohibited medications within protocol-specified timeframes prior to Randomization
• •Has participated in another investigational clinical study within 4 weeks prior to Randomization
• •Has donated or lost ≥1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit
• •Has received cosmetic or other procedures that could interfere with evaluation of vitiligo during the study